Skip to main content

Animations

MJFF Publications

2181 - 2190 of 9016 Results
Title
Year
  • Year
  • 2024
  • 2019
  • 2018
  • 2019
  • 2020
  • 2024
  • 2016
  • 2018
  • 2018
  • 2020
  • Summary Details
    OPEN
    Title: Rapid iPSC inclusionopathy models shed light on formation, consequence, and molecular subtype of α-synuclein inclusions
    Journal Name: Neuron
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1016/j.neuron.2024.06.002
    Citation Count: 27
  • Summary Details
    OPEN
    Title: Efficient RT-QuIC seeding activity for α-synuclein in olfactory mucosa samples of patients with Parkinson’s disease and multiple system atrophy
    Journal Name: Translational Neurodegeneration
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1186/s40035-019-0164-x
    Citation Count: 189
  • Summary Details
    OPEN
    Title: Seeding selectivity and ultrasensitive detection of tau aggregate conformers of Alzheimer disease
    Journal Name: Acta Neuropathologica
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1007/s00401-018-1947-3
    Citation Count: 146
  • Summary Details
    OPEN
    Title: Genomewide association study of Parkinson's disease clinical biomarkers in 12 longitudinal patients' cohorts
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1002/mds.27845
    Citation Count: 189
  • Summary Details
    OPEN
    Title: Is Levodopa Response a Valid Indicator of Parkinson's Disease?
    Journal Name: Movement Disorders
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1002/mds.28406
    Citation Count: 41
  • Summary Details
    OPEN
    Title: Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial
    Journal Name: Nature Medicine
    Publisher: Springer Science and Business Media LLC
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1038/s41591-024-03101-8
    Citation Count: 33
  • Summary Details
    OPEN
    Title: Decreased synaptic proteins in neuronal exosomes of frontotemporal dementia and Alzheimer's disease
    Journal Name: The FASEB Journal
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1096/fj.201600816r
    Citation Count: 409
  • Summary Details
    OPEN
    Title: Cellular Senescence Is Induced by the Environmental Neurotoxin Paraquat and Contributes to Neuropathology Linked to Parkinson’s Disease
    Journal Name: Cell Reports
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.celrep.2017.12.092
    Citation Count: 516
  • Summary Details
    OPEN
    Title: The Parkinson's disease VPS35[D620N] mutation enhances LRRK2-mediated Rab protein phosphorylation in mouse and human
    Journal Name: Biochemical Journal
    Publisher: Portland Press Ltd.
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1042/bcj20180248
    Citation Count: 217
  • Summary Details
    OPEN
    Title: Hierarchical cluster analysis of multimodal imaging data identifies brain atrophy and cognitive patterns in Parkinson’s disease
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2020.11.010
    Citation Count: 58
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.